Understanding how certain signals can reduce inflammation and bone damage in rheumatoid arthritis
Characterizing the negative signaling in dendritic cells and macrophages to attenuate inflammation and bone destruction in rheumatoid arthritis
This study is looking at how certain signals in immune cells can help lessen the long-lasting inflammation and bone damage caused by rheumatoid arthritis, with the goal of finding safer treatment options for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-10762341 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which negative signaling in immune cells, specifically dendritic cells and macrophages, can help reduce chronic inflammation and bone destruction associated with rheumatoid arthritis (RA). The study aims to identify new therapeutic targets that could lead to safer treatments for RA, as current therapies often have severe side effects. By using advanced techniques like RNA sequencing and gene editing in mouse models, the researchers hope to uncover how specific signals can be manipulated to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who are experiencing chronic inflammation and bone destruction.
Not a fit: Patients with rheumatoid arthritis who are not experiencing significant inflammation or bone damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for rheumatoid arthritis that minimize inflammation and bone damage without the severe side effects of current therapies.
How similar studies have performed: Other research has shown promise in targeting negative signaling pathways in immune cells to manage inflammation, suggesting that this approach could be effective.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Li, Yi-Ping — Tulane University of Louisiana
- Study coordinator: Li, Yi-Ping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.